{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T10:09:31Z","timestamp":1787911771895,"version":"build-2784847793"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"DOI":"10.1186\/s12955-024-02279-2","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T06:04:00Z","timestamp":1723183440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational study"],"prefix":"10.1186","volume":"22","author":[{"given":"Elizabeth A.","family":"Griffiths","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae S.","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Nchih","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Johan","family":"Myren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"issue":"18","key":"2279_CR1","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","volume":"124","author":"RA Brodsky","year":"2014","unstructured":"Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804\u201311.","journal-title":"Blood"},{"issue":"7","key":"2279_CR2","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00277-020-04052-z","volume":"99","author":"H Schrezenmeier","year":"2020","unstructured":"Schrezenmeier H, R\u00f6th A, Araten DJ, Kanakura Y, Larratt L, Shammo JM, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Ann Hematol. 2020;99(7):1505\u201314.","journal-title":"Ann Hematol"},{"key":"2279_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.2147\/CLEP.S250250","volume":"12","author":"DL Hansen","year":"2020","unstructured":"Hansen DL, M\u00f6ller S, Andersen K, Gaist D, Frederiksen H. Increasing incidence and prevalence of acquired hemolytic anemias in Denmark, 1980\u20132016. Clin Epidemiol. 2020;12:497\u2013508.","journal-title":"Clin Epidemiol"},{"issue":"2","key":"2279_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/ejh.13640","volume":"107","author":"SJ Richards","year":"2021","unstructured":"Richards SJ, Painter D, Dickinson AJ, Griffin M, Munir T, Arnold L, et al. The incidence and prevalence of patients with paroxysmal nocturnal haemoglobinuria and aplastic anaemia PNH syndrome: A retrospective analysis of the UK\u2019s population-based haematological malignancy research network 2004\u20132018. Eur J Haematol. 2021;107(2):211\u20138.","journal-title":"Eur J Haematol"},{"issue":"Supplement 1","key":"2279_CR5","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1182\/blood-2019-125867","volume":"134","author":"JJ Jalbert","year":"2019","unstructured":"Jalbert JJ, Chaudhari U, Zhang H, Weyne J, Shammo JM. Epidemiology of PNH and real-world treatment patterns following an incident PNH diagnosis in the US. Blood. 2019;134(Supplement 1):3407.","journal-title":"Blood"},{"issue":"11","key":"2279_CR6","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1182\/blood.V108.11.985.985","volume":"108","author":"A Hill","year":"2006","unstructured":"Hill A, Platts PJ, Smith A, Richards SJ, Cullen MJ, Hill QA, et al. The incidence and prevalence of paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in Yorkshire. Blood. 2006;108(11):985.","journal-title":"Blood."},{"key":"2279_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/JBM.S339660","volume":"13","author":"B Fattizzo","year":"2022","unstructured":"Fattizzo B, Cavallaro F, Oliva EN, Barcellini W. Managing fatigue in patients with paroxysmal nocturnal hemoglobinuria: a patient-focused perspective. J Blood Med. 2022;13:327\u201335.","journal-title":"J Blood Med"},{"issue":"3","key":"2279_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/ejh.12543","volume":"95","author":"B Devalet","year":"2015","unstructured":"Devalet B, Mullier F, Chatelain B, Dogn\u00e9 JM, Chatelain C. Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. Eur J Haematol. 2015;95(3):190\u20138.","journal-title":"Eur J Haematol"},{"issue":"2","key":"2279_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.blre.2007.10.002","volume":"22","author":"RA Brodsky","year":"2008","unstructured":"Brodsky RA. Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria. Blood Rev. 2008;22(2):65\u201374.","journal-title":"Blood Rev"},{"issue":"12","key":"2279_CR10","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1056\/NEJMoa061648","volume":"355","author":"P Hillmen","year":"2006","unstructured":"Hillmen P, Young NS, Schubert J, Brodsky RA, Soci\u00e9 G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233\u201343.","journal-title":"N Engl J Med"},{"key":"2279_CR11","unstructured":"Alexion Pharmaceuticals, Inc. Highlights of Prescribing Information: Soliris\u00ae (eculizumab) injection, for intravenous use. Available from: https:\/\/alexion.com\/Documents\/Soliris_USPI.pdf."},{"key":"2279_CR12","unstructured":"Alexion Pharmaceuticals, Inc. Highlights of Prescribing Information: Ultomiris\u00ae (ravulizumab-cwvz) injection, for intravenous or subcutaneous use. Available from: https:\/\/alexion.com\/documents\/ultomiris_uspi."},{"key":"2279_CR13","doi-asserted-by":"publisher","first-page":"204062071987472","DOI":"10.1177\/2040620719874728","volume":"10","author":"RM Stern","year":"2019","unstructured":"Stern RM, Connell NT. Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria. Ther Adv Hematol. 2019;10:2040620719874728.","journal-title":"Ther Adv Hematol"},{"key":"2279_CR14","unstructured":"US Food and Drug Administration. Prescribing information: Ultomiris (ravulizumab). 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761108s023lbl.pdf."},{"issue":"4","key":"2279_CR15","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","volume":"111","author":"RA Brodsky","year":"2008","unstructured":"Brodsky RA, Young NS, Antonioli E, Risitano AM, Schrezenmeier H, Schubert J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111(4):1840\u20137.","journal-title":"Blood"},{"issue":"3","key":"2279_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/ejh.13783","volume":"109","author":"AG Kulasekararaj","year":"2022","unstructured":"Kulasekararaj AG, Griffin M, Langemeijer S, Usuki K, Kulagin A, Ogawa M, et al. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies. Eur J Haematol. 2022;109(3):205\u201314.","journal-title":"Eur J Haematol"},{"key":"2279_CR17","doi-asserted-by":"publisher","first-page":"S378","DOI":"10.1016\/j.jval.2019.04.1847","volume":"22","author":"JL Tran","year":"2019","unstructured":"Tran JL, Kumar S, Eulogio R, Ramirez E, Foschini L, Juusola JL. PSY22 Pain management strategies and activity tracker utilization in a large-scale chronic pain study. Value in Health. 2019;22:S378.","journal-title":"Value in Health"},{"key":"2279_CR18","first-page":"S74","volume":"53","author":"E Ramirez","year":"2019","unstructured":"Ramirez E, Tran JL, Bradshaw B, Kumar S, Tai CG, Foschini L, et al. Longitudinal changes in activity and sleep behaviors from activity trackers are associated with change in depression severity. Ann Behav Med. 2019;53:S74.","journal-title":"Ann Behav Med"},{"issue":"1","key":"2279_CR19","volume":"11","author":"B Bradshaw","year":"2019","unstructured":"Bradshaw B, Konty KJ, Ramirez E, Lee WN, Signorini A, Foschini L. Influenza surveillance using wearable mobile health devices. Online J Public Health Inform. 2019;11(1): e249.","journal-title":"Online J Public Health Inform"},{"issue":"2","key":"2279_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0885-3924(96)00274-6","volume":"13","author":"SB Yellen","year":"1997","unstructured":"Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan E. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. J Pain Symptom Manage. 1997;13(2):63\u201374.","journal-title":"J Pain Symptom Manage"},{"key":"2279_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12955-015-0257-x","volume":"13","author":"S Acaster","year":"2015","unstructured":"Acaster S, Dickerhoof R, DeBusk K, Bernard K, Strauss W, Allen LF. Qualitative and quantitative validation of the FACIT-fatigue scale in iron deficiency anemia. Health Qual Life Outcomes. 2015;13:60.","journal-title":"Health Qual Life Outcomes"},{"issue":"7","key":"2279_CR22","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1136\/ard.2006.065763","volume":"66","author":"V Chandran","year":"2007","unstructured":"Chandran V, Bhella S, Schentag C, Gladman DD. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis. 2007;66(7):936\u20139.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2279_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41687-017-0003-8","volume":"1","author":"RD Hays","year":"2017","unstructured":"Hays RD, Schalet BD, Spritzer KL, Cella D. Two-item PROMIS\u00ae global physical and mental health scales. J Patient Rep Outcomes. 2017;1(1):2.","journal-title":"J Patient Rep Outcomes"},{"issue":"1","key":"2279_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1080\/15402002.2012.636266","volume":"10","author":"L Yu","year":"2011","unstructured":"Yu L, Buysse DJ, Germain A, Moul DE, Stover A, Dodds NE, et al. Development of short forms from the PROMIS\u2122 sleep disturbance and Sleep-Related Impairment item banks. Behav Sleep Med. 2011;10(1):6\u201324.","journal-title":"Behav Sleep Med"},{"issue":"5","key":"2279_CR25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353\u201365.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"2279_CR26","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1213\/ANE.0000000000002864","volume":"126","author":"P Schober","year":"2018","unstructured":"Schober P, Boer C, Schwarte LA. Correlation coefficients: appropriate use and interpretation. Anesth Analg. 2018;126(5):1763\u20138.","journal-title":"Anesth Analg"},{"issue":"11","key":"2279_CR27","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","volume":"21","author":"I Montan","year":"2018","unstructured":"Montan I, L\u00f6we B, Cella D, Mehnert A, Hinz A. General population norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale. Value in Health. 2018;21(11):1313\u201321.","journal-title":"Value in Health"},{"key":"2279_CR28","unstructured":"Northwestern University. PROMIS\u00ae Reference Populations. Available from: https:\/\/www.healthmeasures.net\/score-and-interpret\/interpret-scores\/promis\/reference-populations."},{"issue":"3","key":"2279_CR29","doi-asserted-by":"publisher","first-page":"A24","DOI":"10.1016\/j.jval.2015.03.148","volume":"18","author":"N Tundia","year":"2015","unstructured":"Tundia N, Hass S, Fuldeore M, Wang LL, Cavanaugh T, Boone J, et al. Validation and U.S. population norms of health-related productivity questionnaire. Value in Health. 2015;18(3):A24.","journal-title":"Value in Health."},{"issue":"2","key":"2279_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227709","volume":"15","author":"G Quer","year":"2020","unstructured":"Quer G, Gouda P, Galarnyk M, Topol EJ, Steinhubl SR. Inter- and intraindividual variability in daily resting heart rate and its associations with age, sex, sleep, BMI, and time of year: retrospective, longitudinal cohort study of 92,457 adults. PLoS ONE. 2020;15(2): e0227709.","journal-title":"PLoS ONE"},{"issue":"12","key":"2279_CR31","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.2522\/ptj.20060037","volume":"87","author":"RW Bohannon","year":"2007","unstructured":"Bohannon RW. Number of pedometer-assessed steps taken per day by adults: a descriptive meta-analysis. Phys Ther. 2007;87(12):1642\u201350.","journal-title":"Phys Ther"},{"issue":"11","key":"2279_CR32","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1088\/1361-6579\/aa9047","volume":"38","author":"Z Beattie","year":"2017","unstructured":"Beattie Z, Oyang Y, Statan A, Ghoreyshi A, Pantelopoulos A, Russell A, et al. Estimation of sleep stages in a healthy adult population from optical plethysmography and accelerometer signals. Physiol Meas. 2017;38(11):1968\u201379.","journal-title":"Physiol Meas"},{"issue":"2","key":"2279_CR33","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/cam4.1953","volume":"8","author":"CP Escalante","year":"2019","unstructured":"Escalante CP, Chisolm S, Song J, Richardson M, Salkeld E, Aoki E, et al. Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria. Cancer Med. 2019;8(2):543\u201353.","journal-title":"Cancer Med"},{"issue":"5","key":"2279_CR34","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3324\/haematol.2013.093161","volume":"99","author":"H Schrezenmeier","year":"2014","unstructured":"Schrezenmeier H, Petra M, G\u00e9rard S, Jeffrey S, Alvaro U-I, Jaroslaw PM, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014;99(5):922\u20139.","journal-title":"Haematologica"},{"issue":"1","key":"2279_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s41687-023-00609-4","volume":"7","author":"D Cella","year":"2023","unstructured":"Cella D, Johansson P, Ueda Y, Tomazos I, Gustovic P, Wang A, et al. Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from International PNH Registry patient data. J Patient Rep Outcomes. 2023;7(1):63.","journal-title":"J Patient Rep Outcomes"},{"issue":"10","key":"2279_CR36","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1007\/s11136-021-02925-y","volume":"30","author":"CB Terwee","year":"2021","unstructured":"Terwee CB, Peipert JD, Chapman R, Lai JS, Terluin B, Cella D, et al. Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures. Qual Life Res. 2021;30(10):2729\u201354.","journal-title":"Qual Life Res"},{"key":"2279_CR37","unstructured":"EMA. Summary of Product Characteristics - Ultomiris, INN-ravulizumab. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ultomiris-epar-product-information_en.pdf."},{"issue":"3","key":"2279_CR38","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40744-019-0155-5","volume":"6","author":"W Tillett","year":"2019","unstructured":"Tillett W, Lin CY, Zbrozek A, Sprabery AT, Birt J. A threshold of meaning for work disability improvement in psoriatic arthritis measured by the Work Productivity and Activity Impairment questionnaire. Rheumatol Ther. 2019;6(3):379\u201391.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"2279_CR39","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/jdv.15098","volume":"33","author":"JJ Wu","year":"2019","unstructured":"Wu JJ, Lin C, Sun L, Goldblum O, Zbrozek A, Burge R, et al. Minimal clinically important difference (MCID) for Work Productivity and Activity Impairment (WPAI) questionnaire in psoriasis patients. J Eur Acad Dermatol Venereol. 2019;33(2):318\u201324.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"2279_CR40","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00277-021-04715-5","volume":"101","author":"D Dingli","year":"2022","unstructured":"Dingli D, Matos JE, Lehrhaupt K, Krishnan S, Yeh M, Fishman J, et al. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey. Ann Hematol. 2022;101(2):251\u201363.","journal-title":"Ann Hematol"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-024-02279-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12955-024-02279-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-024-02279-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T14:07:01Z","timestamp":1723212421000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/s12955-024-02279-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2279"],"URL":"https:\/\/doi.org\/10.1186\/s12955-024-02279-2","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]},"assertion":[{"value":"27 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol, informed consent form, recruitment materials and participant materials were reviewed and approved by the Western Institutional Review Board. All patients provided informed consent to participate in the study. Participation in the study was voluntary, and patients were free to withdraw at any time.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Elizabeth A. Griffiths receives honoraria\/grant support and\/or has relationships with AbbVie, Alexion, AstraZeneca Rare Disease, American Society of Hematology, Apellis, The Aplastic Anemia and MDS International Foundation, Celgene\/BMS, CTI BioPharma, Genentech, MediCom Worldwide, Novartis, Physician Educational Resource, PicnicHealth, Taiho Oncology, and Takeda Oncology. Jae S. Min was an employee of and owned stock options in Evidation Health, Inc. at the time of the study. Wei-Nchih Lee is an employee of and owns stock options in Evidation Health, Inc. Jeffrey C. Yu, Yogesh Patel and Karl-Johan Myren are employees of and shareholders in Alexion, AstraZeneca Rare Disease. David Dingli receives honoraria from Alexion, AstraZeneca Rare Disease, Apellis, GSK, Janssen, Novartis, Osseum, Roche, Sanofi, and Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}